Fill out the form to download a preview of this report. The full report is available through the PitchBook Platform.
Medtech outperforms broader markets in Q1 amid volatility
Despite a rocky quarter for public equities, the medtech sector showed relative resilience in Q1 2025. While broader indexes such as the S&P 500 and Nasdaq posted losses, about half of large public medtech companies managed to log gains—boosting the sector’s median performance above the market average. Volatility was sharpest in life sciences, with Tempus AI surging before pulling back and Illumina tumbling more than 45%. Analysts expect double-digit revenue growth in diagnostics, consumer health, and medical devices—although those forecasts may shift as first-quarter earnings roll in. And while valuations continue to decline across the sector, creating potential long-term opportunities, near-term risks remain amid tariff-related disruptions, margin pressures, and macro uncertainty.
Our Q1 2025 Medtech Public Comp Sheet and Valuation Guide tracks metrics for key publicly traded companies that include stock performance, changes in valuation, historical valuations, revenue growth, EBITDA growth, and EBITDA margins. It is constructed using the PitchBook Excel plugin available to subscribers.